L-656,575 (OCP-9-176; Fig. 1 ) is a newly discovered oxacephem1-25 that has a long half-life in mice (18 minutes) and rhesus monkeys (63 minutes)3»4). The compound also has been shown to be effective in the treatment of a variety of experimental Gram-negative bacteremias in mice3'4). In the present study, the in vitro spectrum and potency of L-656,575 in comparison with several other antibiotics against clinical isolates of aerobic and anaerobic bacteria were determined. Cultures Cultures used in this evaluation were all clinical isolates. Each was maintained in the Merck Culture Collection at -70°C on Trypticase Soy agar (TSA; BBL) slants or in 15% skim milk. Each isolate was subcultured from the collection and checked for purity prior to use.
MIC: Agar Dilution The MICs were determined using an agar dilution method. Each compound was prepared ac- Determined by agar dilution assay using multipoint inoculator, inoculum : 105 cfu/spot, Trypticase Soy agar, or Trypticase Soy agar supplemented with 5 % lysed horse blood and 25^g/ml NADfor fastidious organisms. MIC: Lowest concentration showing no visible growth or fewer than 5 discrete colonies. MIC5o: Concentration at which 50% of the strains were inhibited. MIC90 : Concentration at which 90 %of the strains were inhibited. G-MIC: Geometric mean of the MICs.
-: Not determined.
cording to the manufacturer's instructions. Two-fold dilutions were madein appropriate media. One-ml of each antibiotic dilution was mixed with 9 ml of cooled, molten agar in 15 x 100 mmpetri plates to yield final concentrations of drug ranging from 0.008 to 128^g/ml. For the aerobes, TSA was used; for fastidious cultures, TSA supplemented with 5 %lysed horse blood and 25^g/ml nicotinamide adenine dinucleotide was used. For the anaerobes, brain heart infusion (BHI; Difco) agai supplemented with 5^g/ml hemin and 0.5 /big/mi menadione was used. Test plates were inoculated using a Denley Multipoint Inoculator (Sussex, England) designed to deliver 1.0^1 aliquots directly onto the agar surface. A final inoculum of 104, 105 or 106 cfu/spot was used for the aerobes, and 10e cfu/spot for the anaerobes. The aerobes were incubated at 35°C for 18~20 hours, and the anaerobes were incubated at 35°C for 40 hours in a Forma anaerobic chamber (Marietta, Ohio) under an atmosphere of 10% hydrogen, 8% carbon dioxide and 82% nitrogen. The MIG was defined as the lowest concentration of drug showing no distinct growth or less than five discrete colonies/spot. MICs and Minimum Bactericidal Concentrations (MBCs) : Broth Dilution MICs and MBCsfor L-656,575 and ceftazidime against eight isolates of multiply-resistant Pseudomonas aeruginosa were determined using a broth microdilution assay using Dynatech's MIC-2000 system (Chantilly, Virginia). The drugs were prepared as described above, except that Trypticase Soy broth (TSB; BBL) was used, and final drug concentrations in broth ranged from 0.125 to 128 #g/ml. Overnight cultures of the test strains were diluted with TSB and 1.5 [A was added to 50 jul of drug dilution in the test wells. This resulted in an inoculum of approximately 1 x105 cfu/ml. After incubation at 35°C for 20 hours, the test wells were examined for growth. The MICwas recorded as the lowest concentration of drug where no growth was observed. From each well of these assay plates, 1.5 iA was transferred to the surface of drug-free TSA using the MIC2000 system. The agar plates were incubated at 35°C for 20 hours. The lowest drug concentration where no growth or <5 discrete colonies persisted was recorded as the MBC, indicating that at least 96.7% of the initial inoculum (1 x 105 cfu/ml) had been killed.
Results and Discussion
The in vitro antibacterial activity of L-656,575 as compared to that of ceftazidime against a variety of Gram-negative and Gram-positive aerobic clinical isolates is summarized in Table 1 . Overall, L-656,575 demonstrated a broad spectrum of antibacterial activity with excellent potency comparable to ceftazidime. The potency of L-656,575 was superior to that of ceftazidime against isolates of Enterobacter species (Fig. 2, Table 1 ), methicillin-susceptible Staphylococcus aureus and Staphylococcus epidermidis (Fig. 3, Table 1 ), and P. aeruginosa (Table 1 ). The potency of L-656,575 was less than that observed with ceftazidime against isolates of Acinetohacter species, Pseudomonas species other than P. aeruginosa, and Streptococcus pyogenes. Both drugs were comparable in potency against the other clinical isolates tested ( Table 1) .
The in vitro antibacterial activity of L-656,575 and other cephalosporins against selected anaerobic isolates is summarized in Table 2 . Moxalactam was the most active compound, followed in relative activity by ceftriaxone, cefpirome, ceftazidime and L-656,575. L-656,575 demonstrated good activity against several of the anaerobic isolates, but relative potency was the lowest when the drug was compared to the other four cephalosporins tested.
The comparative activities of L-656,575 and selected^-lactam antibiotics against fifteen multiplyresistant strains of P. aeruginosa are summarized in Table 3 . The data show that L-656,575 and imipenem were the most active compounds. At drug concentrations of <16 /^g/ml, only imipenem had better activity than L-656,575 against these multiply-resistant isolates. Also of significant importance was the fact that L-656,575 was not cross-resistant with the other /3-lactam antibiotics tested.
When the MBC/MICratios for L-656,575, imipenem, and ceftazidime against eight isolates of multiply-resistant P. aeruginosa were compared, the L-656,575 ratio was never more than 1.0, whereas those for both imipenem and ceftazidime exceeded 1.0 against four and three of these isolates, respectively (Table 4) . Microscopic examinations of broth cultures of P. aeruginosa at subinhibitory concentrations of the compoundrevealed the predominance of long chains of elongated cells (not shown). These results suggest that L-656,575 has a high affinity for penicillin binding proteins of Pseudomonas, and that it may bind preferentially to PBP-3 in this organism. In a separate study using an agar dilution method, potent in vitro activities were demonstrated for L-656,575 against laboratory isolates of Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca and P. aeruginosa known to possess either plasmid or chromosomally-mediated /3-lactamases, even at an inoculum concentration of 106 cfu/spot. These data suggest that the compoundis very resistant to hydrolysis by bacterial $-lactamases (Table 5 ).
In conclusion, L-656,575 is a novel 2-methyloxycephalosporin with in vitro antibacterial activity superior to ceftazidime against Enterobacter species, methicillin-susceptible S. aureus and S. epidermidis, and multiply-resistant P. aeruginosa. This compound is active against /3-lactamase derepressed Enterobacteriaceae and ceftazidime-resistant P. aeruginosa.
